Incidence and Outcomes of Acute Kidney Injury in Trauma Patients Admitted to Critical Care

NCT ID: NCT05381493

Last Updated: 2022-05-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

171 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2022-05-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute kidney injury (AKI) is a common complication that increases lenght of stay and mortality in trauma patients admitted to the intensive care unit (ICU). The aim of this study is to identify the incidence and outcomes of trauma patients, defined by Kidney Disease Improving Global Outcomes (KDIGO) criteria, at single center level 3 ICU.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Trauma can cause high mortality and morbidity by affecting different organ systems. Acute kidney injury (AKI) is a common complication in trauma patients admitted to the intensive care unit (ICU). Direct kidney injury, hypotension, hypoperfusion, rhabdomyolysis, abdominal compartment syndrome, sepsis and critical care medications are possible causes of AKI in trauma patients. The incidence of AKI can be up to 10%, and mortality rate up to 60-80% in trauma patients. Since AKI is not only a rare complication but also a risk factor for mortality in critically ill trauma patients, it is essential to establish a strategy to prevent AKI and related complications, to determine the incidence and risk factors of AKI, and to improve patients outcomes. Survivors of AKI may have variable recovery of kidney function and might prone to late morbidity and mortality. In this study incidence of AKI was defined using the KDIGO criteria according to the change of serum creatine levels.

171 all type of trauma patients admitted to level 3 ICU, from January 2014 to December 2018 included the retrospectve observational study. Demographic data, type of injury, rates of complications, risk factors for AKI, mortality, lenght of stay (LOS) in ICU were evaluated. Acute Physiology and Chronic Health Evaluation (APACHE II and IV) score, Simplified Acute Physiology Score (SAPS II and III), Glasgow Coma Scale (GCS), Injury Severity Score (ISS) and, Trauma Injury Severity Score (TRISS) were calculated on the day of admission. AKI was defined using the KDIGO criteria according to the serum creatinine. The SPSS 11.5 program was used for statistical analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury Trauma; Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all type of trauma patients admitted to level 3 ICU, from January 2014 to December 2018

Exclusion Criteria

\-
Minimum Eligible Age

18 Years

Maximum Eligible Age

97 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bengi Şafak

UNKNOWN

Sponsor Role collaborator

Keziban Sanem Çakar Turhan

UNKNOWN

Sponsor Role collaborator

Mustafa Onur Karaca

UNKNOWN

Sponsor Role collaborator

Uğur Aydoğan

UNKNOWN

Sponsor Role collaborator

Ali Abbas Yılmaz

UNKNOWN

Sponsor Role collaborator

Mustafa Kemal Bayar

UNKNOWN

Sponsor Role collaborator

Ankara University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Süheyla Karadağ Erkoç

Anesthesiology and Reanimation

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Süheyla Karadağ Erkoç

Role: PRINCIPAL_INVESTIGATOR

Ankara University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Süheyla Karadağ Erkoç

Ankara, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AnkaraUTraumaAKI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.